KABE (complexed abiraterone alcohol) for Prostate Cancer

KABE (Abiraterone) is an enhanced KinetiSol® reformulation of the approved drug Zytiga®, with multiple-fold better bioavailability than other available abiraterone acetate products.  KABE (Abiraterone) tablets are comprised of complexed abiraterone alcohol rather than the abiraterone acetate prodrug used in Zytiga®.  This is important in that KABE may improve the treatment of metastatic castration-resistant prostate cancer (mCRPC) and metastatic high-risk castration-sensitive prostate cancer (mCSPC), in non-responding patients in whom poor bioavailability may constrain the effectiveness of the treatment.